



# THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### A new model for NTHi middle ear infection in the Junbo mutant mouse

**Citation for published version:**

Hood, D, Moxon, R, Purnell, T, Richter, C, Williams, D, Anvari Azar, A, Crompton, M, Wells, S, Fray, M, Brown, SDM & Cheeseman, MT 2016, 'A new model for NTHi middle ear infection in the Junbo mutant mouse' *Disease Models & Mechanisms*, vol. 9, no. 1, pp. 69-79. DOI: 10.1242/dmm.021659

**Digital Object Identifier (DOI):**

[10.1242/dmm.021659](https://doi.org/10.1242/dmm.021659)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Publisher's PDF, also known as Version of record

**Published In:**

*Disease Models & Mechanisms*

**Publisher Rights Statement:**

© 2015. Published by The Company of Biologists Ltd

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



# A new model for NTHi middle ear infection in the *Junbo* mutant mouse

Derek Hood<sup>1</sup>, Richard Moxon<sup>2</sup>, Tom Purnell<sup>1</sup>, Caroline Richter<sup>1</sup>, Debbie Williams<sup>1</sup>, Ali Azar<sup>4</sup>, Michael Crompton<sup>1</sup>, Sara Wells<sup>3</sup>, Martin Fray<sup>3</sup>, Steve D.M. Brown<sup>1</sup>, Michael T. Cheeseman<sup>1,3,4</sup>

<sup>1</sup> MRC Mammalian Genetics Unit, MRC Harwell

<sup>2</sup> Department of Paediatrics, University of Oxford Medical Sciences Division. John Radcliffe Hospital, Oxford

<sup>3</sup> Mary Lyon Centre, MRC Harwell

<sup>4</sup> The Roslin Institute and Royal (Dick) School of Veterinary Studies  
University of Edinburgh

## SUMMARY STATEMENT

Acute otitis media is an important disease in children. We describe a new infection model for translational research that uses the Mecom mouse mutant intranasally inoculated with non-typeable *Haemophilus influenzae*.

## ABSTRACT

Acute otitis media, inflammation of the middle ear, is the most common bacterial infection in children and as a consequence is the most common reason for antimicrobial prescription to this age group. There is currently no effective vaccine for the principal pathogen involved, non-typeable *Haemophilus influenzae* (NTHi).

The most frequently used and widely accepted experimental animal model of middle ear infection is in chinchillas, but mice and gerbils have also been used. We have established a robust model of middle ear infection by NTHi in the *Junbo* mouse, a mutant mouse line that spontaneously develops chronic middle ear inflammation under specific pathogen free conditions. The heterozygote *Junbo* mouse (*Jbo/+*) bears a mutation in a gene (*Evi1*, also known as *Mecom*) that plays a role in host innate immune regulation; pre-existing middle ear inflammation promotes NTHi middle ear infection. A single intranasal inoculation with NTHi produces high rates (up to 90%) of middle ear infection and bacterial titers ( $10^4$  to  $10^5$  CFU/ $\mu$ l) in bulla fluids. Bacteria are cleared from the majority of middle ears between day 21 and 35 post-inoculation but remain in approximately 20% of middle ears at least up to day 56 post-infection. The expression of TLR-dependent response cytokine genes is elevated in the middle ear of the *Jbo/+* mouse following NTHi infection. The translational potential of the *Junbo* model for studying antimicrobial intervention regimens was shown using a 3-day course of Azithromycin to clear NTHi infection, and its potential use in vaccine development studies by demonstrating protection in mice immunized with killed homologous, but not heterologous, NTHi bacteria.

## INTRODUCTION

Acute otitis media (AOM) is primarily caused by the bacterial commensal pathogens non-typeable *Haemophilus influenzae* (NTHi), *Streptococcus pneumoniae* (pneumococcus), and *Moraxella catarrhalis*. AOM is the most common bacterial infection in children and as a consequence is the commonest reason for antibiotic prescription during childhood accounting for 24.5 million physician office visits per year in the US (Bakaletz, 2009). The global health burden of AOM is significant; of an estimated 709 million cases per year, 31 million children go on to develop chronic suppurative OM (with otorrhea i.e. perforation of the tympanic membrane and drainage of pus) and an estimated 21,000 deaths occur each year from complications such as meningitis (Monasta et al., 2011).

The chinchilla otitis media model was first developed to study pneumococcus infection (Giebink et al. 1976). It has subsequently become the most frequently used model for NTHi infection studies, vaccine development, and is considered to be a robust, reproducible model for polymicrobial infections (Bakaletz, 2009). Following direct inoculation of the chinchilla bulla, NTHi can form a biofilm that promotes bacterial survival against the host response and treatment (Jurcisek and Bakaletz, 2007; Brockson et al., 2014). In addition to the chinchilla, there is increasing use of inbred strains of mice and mouse mutants in OM research (Ryan et al., 2006; Sabirov and Metzger, 2008, Hernandez et al., 2015). In chinchillas and mice, direct injection of bacteria into the middle ear (ME) bulla is efficient and allows the dose to be controlled, but intranasal (IN) inoculation that mimics natural ascending Eustachian tube (ET) infection produces only sporadic ME infection in mice (Ryan et al., 2006) and no ME infection in chinchillas (Bakaletz, 2009). However, IN inoculation of the chinchilla produces sustained infection of the ME when it is used in conjunction with barotrauma (lowering pressure in the ME) (Giebink et al., 1979) or following virus infection (Giebink, 1981). In mice, IN inoculation results in colonisation of

the nasopharynx (NP) and subsequent ME infection is enhanced by repeated IN inoculation (Sabirov and Metzger, 2006), when IN inoculation is used in conjunction with virus infection (McCullers et al., 2007; Short et al., 2013) or barotrauma (by raising environmental air pressure) (Stol et al., 2009).

Mice with mutations in TGF- $\beta$  signaling pathway genes that modulate pro-inflammatory responses or mutations that lead to ET malformation are predisposed to develop OM spontaneously without the need for bacterial challenge and a number of these genes are also implicated in modulating susceptibility to human OM (review by Rye et al., 2010).

In this study we focus on NTHi induced ME infection in the *Junbo* mouse, a mutant mouse line that spontaneously develops chronic ME inflammation under specific pathogen free (SPF) conditions. The heterozygote *Junbo* mouse (*Jbo/+*) bears an Asn763Ile mutation in the gene encoding the transcription factor Evi1, also known as Mecom (Parkinson et al., 2006). One mechanism that may underlie the predisposition to OM in *Jbo/+* mice is that Evi1 is a negative regulator of NF $\kappa$ B and the loss of function Evi1 *Junbo* mutation exacerbates NTHi induced inflammation in the lung (Xu et al., 2011).

We hypothesized that the ME inflammation in *Jbo/+* mice could provide a niche in which, after IN challenge, bacteria would establish infection following contiguous spread along the ET. As a proof of this concept and its utility as a validated animal model of otitis media, we used the human commensal pathogen NTHi to establish ME infection. We have characterized the dynamics and host responses to NP colonization and OM, using multiple, genetically distinct NTHi strains. Our data demonstrate the utility of the *Jbo/+* model for testing immunization and antibiotics strategies aimed at the prevention or treatment of NTHi infection of the ME.

## RESULTS

### **NTHi inoculated intranasally infect the ME of *Jbo/+* mice for at least 56 days**

We have successfully established a robust model of ME infection using a single IN inoculation with the commensal pathogen NTHi in the *Junbo* mouse. Seven well studied and unrelated NTHi isolates from human OM and one from lower respiratory tract disease (strain 2019) were inoculated IN ( $10^8$  CFU) into 8-week-old SPF *Jbo/+* mice then sampled after culling on day 7 post-infection. For seven of the NTHi isolates, high bacterial titers of  $10^4$ – $10^5$  CFU/ $\mu$ l were obtained from 30-90% of infected ME bullae (Fig. 1A and 1C). Infection with NTHi 176 was unsuccessful. Strains NTHi 162 and 375 were chosen as the principal test strains for subsequent experiments.

The ME infection rates (Fig. 1B) and titers (Fig. 1D) were not significantly different when inocula ranging from  $10^4$  to  $10^8$  CFU NTHi 162 were used. Following an IN challenge of  $10^3$  CFU, a significant increase in ME NTHi load 7 days post-infection was detected ( $10^{4.7}$  CFU/ $\mu$ l,  $10^{4.2}$  -  $10^{5.3}$  95% CI,  $n=7$ ,  $P=0.000185$ , 1 sample t-test), however the ME infection rate was reduced with this low inoculum size (24% vs 75% for  $10^3$  and  $10^6$  CFU 162sr inoculation groups ( $n=15$ ) respectively,  $P=0.000178$ ).

The potential for rapid transfer of bacteria from the NP to the ME was demonstrated following IN inoculation with  $10^8$  CFU of strain NTHi 162lux. Within minutes a bioluminescent signal was distributed along the full length of the NP (Fig. 2A), NTHi were adjacent with the ET opening even though the inoculation volume (10  $\mu$ l) is small relative to that of the nasal cavity (30  $\mu$ l) (Maronpot et al., 1999). Subsequent spread and dilution of the inoculum resulted in insufficient signal to permit direct monitoring of bacterial movement from the NP. We therefore administered IN  $10^8$  FITC labeled 1  $\mu$ m microspheres as a marker for ET ascension. Five minutes after administration the numbers of microspheres in histological sections of the ET were not significantly different between 9-week-old *Jbo/+*

mice (median 28 per mm, 95% CI, 12-77) and wild-type littermate mice (median 29 per mm, 95% CI, 8-39;  $P=0.6569$ ).

We examined ascending ET infection in 8-week-old *Jbo/+* mice by sampling bulla fluids and detected NTHi at 1 hr, 3 hr, 6 hr and 24 hr post IN inoculation with  $10^6$  CFU NTHi strain 162sr. With a 10 CFU/ $\mu$ l detection limit for NTHi, ME bulla fluid infection rates were high ( $\geq 70\%$ ) from 1 hr onwards (Fig. 2B). ME NTHi titers were  $10^{3.2}$ - $10^{3.7}$  CFU/ $\mu$ l at 1-6 hr and increased significantly to  $10^{4.7}$  CFU/ $\mu$ l ( $10^{4.2}$  - $10^{5.2}$  95% CI) by 24 hr post-inoculation (Fig. 2D). Over a 56 day time course ME infection rates were consistently high ( $\geq 60\%$ ) 4-14 days post-inoculation then declined to  $\sim 20\%$  and were maintained at this rate over the period from day 35-56 (Fig. 2C). ME titers peaked at day 10 and remained at  $\sim 10^4$  - $10^5$  CFU/ $\mu$ l up to day 56 (Fig. 2E), the last period sampled.

There was a strong positive association ( $P=2.62E-16$ ) between NTHi infection in the ME and NP (Table S1) and ME/NP co-infection declines with time (Fig. S1). The recovery of NTHi by NP washing is only semi-quantitative and the counts were generally low,  $10^{1.1}$  CFU ( $10^{0.9}$  - $10^{1.1}$  95% CI,  $n=86$  in 50  $\mu$ l sample of 200  $\mu$ l wash volume).

The histology of the NTHi infected middle ear was examined in 12-week-old *Jbo/+* mice at day 7 post IN inoculation. To maintain the anatomical integrity of the bulla contents the tympanic membrane (TM) was not opened. A necrotic caseous core of neutrophils is surrounded by viable and apoptotic neutrophils (cleaved caspase 3 positive) and an outer, variably thick, band of foamy macrophages (F 4/80 positive) (Fig. 3A-E). There were variable amounts of amorphous extracellular chromatin within the caseous areas (Fig. 3F). The larger accumulations were histone 3 negative, but smaller granular aggregates were histone 3 positive (Fig. 3G). Neutrophil leukocytes were present in the ET lumen and ET mucosa at its junction with the NP and in the ET lumen where it opens into the ME (Fig. 3H, Fig. 3I). The NP mucosa adjacent to the ET opening was not inflamed. Taken together this

data is consistent with an interpretation that the relatively large NTHi populations in the ME act as a reservoir for re-infection through contiguous descending spread from the ME to the NP along with efflux of exudate. The overall histology of chronic OM in 12-week-old *Jbo/+* mice was not significantly different between NTHi challenged and non-challenged mice. 60% (median, 95% CI, 50-75) and 67% (33-81;  $P=0.5339$ ) of the bulla was occupied by neutrophils and foamy macrophages and the thickness of middle ear mucosa was 100  $\mu\text{m}$  (84-104) and 111  $\mu\text{m}$  (79-150;  $P=0.086$ ) in NTHi challenged and non-challenged *Jbo/+* mice respectively.

Gram staining failed to reveal Gram-negative coccobacilli in foamy macrophages, and the presence of abundant karyorrhectic nuclear debris in the necrotic core confounded unequivocal demonstration of Gram-negative bacteria in the center of the mass. To localize NTHi bacteria in the bulla we used in situ hybridization targeting the 16S rRNA of NTHi and this gave strong signals from the bulla exudate but not elsewhere in head tissues from *Jbo/+* mice challenged with NTHi 162. NTHi hybridization signals comprised punctate or larger aggregates and were scattered throughout bulla exudate but were less frequent in the caseous core (Fig. 2 J, K). Evidence consistent with the presence of significant or mature biofilm was not found. In contrast, NTHi hybridization signals were absent in non-challenged *Jbo/+* control mice (Fig. 2 L, M).

### **Bulla fluids are critical for NTHi infection in different mouse backgrounds**

97.2% (71/73) of NTHi inoculated 8-week-old wild-type mice had healthy ears (a clear TM with no detectable intra-bulla fluid) and PBS washes were NTHi culture negative. Only two (of 73) NTHi inoculated wild-type mice had OM; both had unilateral disease and the bulla fluids were NTHi culture positive, indicating that NTHi infection of the wild-type mouse ME



was indeed a rare event. A proportion of NTHi inoculated *Jbo/+* mice have unilateral or no OM (see below). Only 1.4% (3/206) of PBS washes from these healthy *Jbo/+* ears gave NTHi positive cultures.

NTHi infection in the *Jbo/+* mouse did not alter the frequency of OM. The incidence of ME bulla fluids, judged by TM opacity, in  $n=81$  NTHi challenged *Jbo/+* mice aged 8 weeks and inoculated with  $10^8$  CFU NTHi (pooled data from experiments with 7 NTHi strains) and sampled 7 days later was not significantly different to previously published data on non-challenged 8 week *Jbo/+* mice ( $n=54$ ) (Cheeseman et al., 2011); bilateral OM 85.1% vs 77.8%, unilateral OM 13.6% vs 13.0%, no macroscopic ME disease 1.2% vs 9.3%, each respectively ( $P=0.10$  2x3 Fisher exact test).

8-week-old *Jbo/+* mice congenic on a BALB/c background also had a spontaneous OM phenotype and NTHi ME infection rates and titers were similar to those seen in *Jbo/+* mice congenic on the standard C3H/HeH background used in this study. For other mutant mouse lines with a spontaneous OM phenotype when infected by NTHi, 8-14 week old *Tgif* (*Tgif*<sup>-/-</sup>) (Tateossian et al., 2013) has lower ME titers and 7-8 week old *Jeff* (*Jf*<sup>+</sup>) (Hardisty-Hughes et al., 2006) have the lowest ME titers and infection rates compared to *Jbo/+* (Fig. S2). Together these results indicate that pre-existing inflammation and ME bulla fluid is a necessary requirement for NTHi colonization/infection. IN inoculation with NTHi does not efficiently induce OM in the healthy fluid-free ME of either wild-type or *Jbo/+* mice nor does it increase the incidence of bulla fluids in *Jbo/+* mice. Furthermore, mice with different OM-related mutations behave differently with respect to NTHi infection and do not simply facilitate a non-specific access of bacteria to infect the ME.

## The role of indigenous mouse ME flora

The natural flora of the *Jbo/+* mouse has the potential to influence the outcome of NTHi infection experiments. A requirement for indigenous NP flora in spontaneous OM was investigated by generating germ free (GF) *Jbo/+* mice. The incidence of OM in the GF and specific pathogen free (SPF) *Jbo/+* mice was the same but its onset was slightly later, at 5 weeks rather than 4 weeks, under GF conditions. The histological features of OM in GF *Jbo/+* mice were inflammatory thickening of the bulla mucosa and accumulation of neutrophil leukocytes and foamy macrophages in the bulla fluid. There were occasional plant-based foreign bodies from bedding or food in the bulla fluid (Fig. 4). This histopathology is indistinguishable from the previously described pattern in SPF *Jbo/+* mice (Parkinson et al., 2006; Cheeseman et al., 2011). Thus, normal flora microbial is not an absolute requirement for the *Jbo/+* mouse to develop OM.

SPF *Junbo* mice were utilized in our standard NTHi infection experiments. Routine microbiological surveillance of the NP in sentinel mice from our SPF animal facility revealed the mice were free of all FELASA listed mouse pathogens and the presence of the following NP commensals (NP positive culture as a percentage of  $n=1150$  mice sampled): *Enterobacter* spp 2.8%, *E. coli* 2.3%, *Lactobacillus* spp 0.7%, *Proteus* spp 22.7%, *Staphylococcus aureus* 62.9%, *Staphylococcus* spp (not *Staph. aureus*) 56.2%, alpha-hemolytic *Streptococcus* spp 94.3%, and *Streptococcus* spp (not beta-hemolytic or *S. pneumoniae*) 37.0%. The effect of ME commensal bacteria on NTHi titers in ME bulla fluids was investigated in 12 week old *Jbo/+* mice inoculated with  $10^6$  CFU NTHi 162sr by comparing growth on selective (antibiotic) and non-selective plates. NTHi titers were very similar when ME bulla fluids had pure NTHi cultures ( $10^{4.5}$  CFU/ $\mu$ l;  $10^{4.3}$ - $10^{4.8}$  95% CI,  $n=59$ ) or mixed cultures with NTHi and *Proteus* or other commensals ( $10^{4.5}$  CFU/ $\mu$ l;  $10^{4.3}$ - $10^{4.7}$ ,  $n=74$ ).

## Population dynamics of NTHi infection

When two NTHi strains able to be monitored independently, 162lux and 375, were co-inoculated into 8-10 week old *Jbo/+* mice, 83% of ME gave rise to a mixed culture of both strains at day 1 but 71% of ME gave a monoculture of one or the other, but not both, strains at day 7. In this period ME infection rates remained high, ME titers of each strain were comparable in co-infections, but NTHi 162lux monocultures predominated by day 7 (Fig. 5). Of interest, in at least one mouse the right and left ME were infected by monoculture of the alternative NTHi strains indicating that each middle ear can operate as a separate compartment for growth and selection within the same animal.

## *Jbo/+* mouse produces an innate immune response in the ME to NTHi infection

The host innate immune response was assessed in the ME of 8-10 week old *Jbo/+* mice following NTHi infection using 8-10 week old *Jbo/+* GF mice as a sterile inflammatory baseline control. We chose to study expression of TLR response cytokine genes that are likely to be activated by NTHi ligands binding to TLR-receptors (e.g. TLR2, TLR4, TLR9) that are expressed by macrophages, monocytes and neutrophils (<http://www.immgen.org>) and are relevant to OM and AOM (Juhn et al., 2008; Kaur et al., 2015). We used bulla samples collected from mice at 1, 4, 7 and 14 days post-inoculation with  $10^6$  CFU NTHi 375 when NTHi infection rates were  $\geq 70\%$  (Fig. 6A) and bacterial titers in the range  $10^{4.4}$ - $10^{4.7}$  CFU/ $\mu$ l (Fig. 6B). Gene expression patterns varied; IL-17a, Tnfa, Ccl3 and Ccl4 showed the highest relative upregulation (4 to 64 fold) throughout this time course relative to GF baseline controls (Fig. 5C); IL-1b, IL-12a, declined slightly at the day 3 time point but were otherwise moderately elevated ( $\geq 2$  fold). Vegf, a marker for hypoxia in the inflammatory environment, did not change ( $\leq 2$  fold) (Fig. 6D), Ccl5 and IL-6 were elevated at day 1 but declined to baseline levels by day 14 (Fig. 6E).

The combined data from NTHi infections indicate that the *Jbo*/<sup>+</sup> mouse is an important new infection model that can facilitate study of NTHi pathogenesis and OM disease. ME infection of mice is achieved efficiently by a single IN inoculation with NTHi, producing high rates of ME infection and bacterial titers in bulla fluids that are sustained in a proportion of ME up to 56 days post-inoculation. NTHi co-exists with indigenous bacteria in SPF mice but still induces a host innate response following infection. Having established a robust NTHi infection model for the study of OM pathogenesis we then explored its potential translational utility in challenge (vaccines) studies and treatment (antimicrobials).

### **An adaptive immune response in the *Jbo*/<sup>+</sup> mouse is protective against NTHi challenge with a homologous NTHi strain**

Following the advent of multivalent pneumococcal vaccines, NTHi is now the leading cause of OM (Benninger, 2008) but currently there are no effective vaccines against this bacterium. An initial assessment of the *Jbo*/<sup>+</sup> mouse as a model for vaccine studies was made by immunizing 5-week-old *Jbo*/<sup>+</sup> mice subcutaneously with killed NTHi 162. At 12 weeks, mice were inoculated IN with live NTHi 162sr, the homologous strain. Terminal assessment at day 7 post-inoculation revealed significantly reduced ME infection rates compared to PBS immunized control animals (15% versus 81%,  $P=9.15E-12$ ) (Fig. 7 A). In mice that were NTHi culture positive, ME infection was unilateral and titers were significantly lower to those in PBS-immunized controls ( $P=1.41E-03$ ) (Fig. 7 B). For mice that were immunized with killed heterologous NTHi strains 176 or 375, then inoculated IN with live strain 162sr, there was no significant protection indicated by ME infection rates, however, bacterial titers were  $\sim 1 \log_{10}$  lower compared to PBS-immunized controls ( $P=0.00015$  and  $P=0.0011$  for 176 and 375 respectively) (Fig. 7 A and 7 B). Thus, the antibody response against NTHi in the *Jbo*/<sup>+</sup> mouse can provide protection and can discriminate between homologous and heterologous NTHi challenge.

### **Azithromycin treatment eliminates NTHi ME infection**

Antibiotic resistance in the clinical setting is on the increase for commensal pathogens (Benninger, 2008); this has the potential to impact on treatment regimens for disease caused by NTHi, including OM. To make a preliminary assessment of the *Jbo*/+ mouse model for testing new antimicrobials or antibiotic delivery strategies we treated 8-week-old *Jbo*/+ mice with a 3-day course of Azithromycin (100 mg/kg) starting at day 4 post-inoculation with NTHi 162. Compared to untreated mice where ME infection was detected on day 1 post-inoculation and was maintained in  $\geq 80\%$  of ME at titers of  $10^4$ - $10^5$  CFU/ $\mu$ l from day 4-14 (Fig. 8 A and 8 C), NTHi had been eliminated from all ME bulla fluids of azithromycin treated mice (Fig. 8 B and 8 D). This data provides initial evidence of the potential for the *Jbo*/+ mouse to be used for efficient screening of antimicrobial agents or treatment regimens for OM.

### **IN challenge with the pneumococcus.**

To investigate whether ME infection could be achieved with the other major human otopathogen, 8-week-old *Jbo*/+ mice were inoculated IN with  $10^5$  CFU *S. pneumoniae* strain D39 in 10  $\mu$ l (supplied by Peter Andrew, University of Leicester, UK) (Haste et al., 2014). One day post-inoculation, the ME infection rate (63%) and titers ( $10^{4.2}$  CFU/ $\mu$ l,  $10^{3.4} - 10^{4.9}$  95% CI,  $n=15$ ) were similar to those seen following NTHi challenge. However on day 2, unlike with NTHi, there were unexpected deaths in 5 of 15 mice with this relatively low dose, and a small volume that would not be expected to infect the lower airway. The experiment was immediately terminated and retro-orbital blood samples from 3 of 10 survivors indicated bacteremia. In the surviving mice the ME infection rate was 50% and titers of  $10^{4.5}$  CFU/ $\mu$ l ( $10^{2.8} - 10^{6.2}$  95% CI,  $n=10$ ) were attained. Thus, the *Jbo*/+ infection model can support ME pathogens other than NTHi but for the pneumococcus this needs to be further explored using appropriately attenuated strains with reduced virulence.

## DISCUSSION

A recent review of the use of animals in OM research concluded there is a need to improve our current animal models, develop new ones and use a diversity of species to ensure that differences between any one species and humans do not bias our data (Li et al., 2013). In this work we show that *Junbo*, a mutant mouse line that develops OM spontaneously, has significant potential for ME infection studies as it can be reproducibly infected with a single IN inoculum of NTHi. NTHi rapidly ascends the ET and colonizes the ME. NTHi infection is detected in bulla fluids at 1 hr, titers peaked between day 7-14 and 20% of individual ME were infected up to day 56. Mouse ME bacterial titers ( $10^4$ - $10^5$  CFU/ $\mu$ l) are comparable to those reported in direct inoculation of the chinchilla ME ( $10^6$  - $10^7$  CFU/ml) albeit that the volume of material recovered from the mouse is substantially less. Infection in the chinchilla was cleared by day 35 using the same NTHi strain set utilised in our study (Bouchet et al., 2003).

The *Junbo* infection model provides a number of new perspectives on OM pathogenesis. In keeping with other animal models, the ME of wild-type mice are not efficiently infected by NTHi following IN inoculation. Microspheres that are similar in size to NTHi are readily translocated into the ET in both wild-type and *Junbo* mice and by this measure there is no obvious deficit in ET barrier function in *Junbo* mice. Other studies have shown that co-infection with viruses such as adenovirus promotes NTHi infection in the chinchilla ME (Bakaletz, 2009) and influenza virus promotes pneumococcus ET ascension (McCullers et al., 2007) and ME infection (Short et al., 2013). Taken together, these findings suggest that coincident inflammation is a pre-disposing factor promoting successful ME bacterial colonization and infection via direct epithelial injury and/or increased mucosal barrier permeability leading to ME fluid accumulation and creation of a new niche for

colonizing bacteria. The hypoxic inflamed ME in *Junbo* mice (Cheeseman et al., 2011) may favor the growth of microaerophilic bacteria such as NTHi.

The strong association between the incidence of ME and NP infection, the high number of NTHi in the ME relative to NP and exudate along the length of the ET suggests the ME can act as a reservoir for NP re-infection. The implication is that the ME compartment is not an evolutionary dead end for NTHi. The ME niche will impose strong selection pressure through altered nutrient, oxygen and host defense parameters compared to the NP environment, factors consistent with the evolution of a repertoire of adaptive gene expression, for example the phase variation characteristic of NTHi strains.

The generation of GF *Junbo* mice revealed that bacteria are not necessary for OM to develop but accelerate its onset. The presence of foreign bodies in histological sections of bulla fluids shows that fine particulate matter can gain access to the ME via the ET. This suggests physical irritants, which may include exposure to ammonia in laboratory mice, can act as inflammatory stimuli. The importance of non-microbial inflammatory stimuli in OM is not surprising given the established role of cigarette smoke as a risk factor in OM (Cayé-Thomasen et al., 2013).

Perturbation of innate immunity in the *Junbo* mouse via impaired Evi1 negative regulation of NFkB (Xu et al., 2011) is likely to contribute to the inflammatory OM phenotype and susceptibility to NTHi infection. In this regard *Junbo* has similarities to other mouse mutants with innate immunity deficits (Leichtle et al., 2011) where inflammation and bacterial clearance following intra-bulla challenge is prolonged compared to immune competent inbred strains such as C57BL/6 (Ryan et al., 2006).

The global activation of an innate immune response following introduction of NTHi directly into the naïve mouse ME bulla has been characterized in a recent infection study. Bulla inflammatory cells and mucosal hyperplasia and inflammation peaked at 2 days and

returned to baseline by 7 days. Mucosal gene expression showed a temporal pattern of gene clusters associated with neutrophil and macrophage recruitment and activation leading to resolution. It was suggested that dysregulation of pro- and anti-inflammatory signalling may be an important feature of chronic or recurrent OM (Hernandez et al, 2015).

NTHi express a number of ligands that may be recognized by different TLRs. In the context of experimental OM in the mouse, membrane associated NTHi ligands such as peptidoglycan and peptidoglycan associated proteins (e.g. P6) are TLR2 ligands and lipopolysaccharide activates TLR2 and TLR4 signalling (Leichtle et al., 2009). Destruction of NTHi in the OM lesion is likely to release bacterial DNA and CpG motifs that are ligands for TLR9 (Leichtle et al., 2012) and bacterial RNAs (see below) are ligands for TLR7 and TLR8. In children with AOM, TLR2 and TLR4 are significantly upregulated in bacterial culture positive bulla fluids compared to culture negative bulla fluids (Kaur et al., 2015). These TLRs signal through MyD88 to upregulate pro-inflammatory cytokines.

In the *Junbo* mouse, antigen-presenting cells capable of recognizing bacterial ligands for TLRs are present in the bulla fluids at the initiation of infection, and the bulla fluids were culture positive for NTHi throughout the 14-day time course of the experiment. We cannot exclude the possibility that TLR ligands from endemic bacteria contribute to expression of response cytokines, but we were able to exclude this variable from the baseline control by using bulla fluids from sterile inflammation in GF *Junbo* mice. In NTHi challenged *Junbo* mice there is upregulation of TNFa, IL1-b, IL12a, Ccl5, and IL6 which are implicated as inflammatory mediators in OM (Juhn et al., 2008). Furthermore, TNFa, IL1-b, IL6, Ccl3, and Ccl4 are differentially expressed in culture positive compared with culture negative middle ear fluids from children with AOM (Kaur et al., 2015). IL17a is important in neutrophil inflammation in NTHi exacerbation of COPD (Roos et al., 2015). Expression of IL6 and Ccl5 declined after initial NTHi infection whilst other cytokines showed sustained upregulation.



Vegfa is a marker of chronic inflammatory hypoxia in *Junbo* OM (Cheeseman et al., 2011) but Vegfa expression was unaltered by NTHi infection. These results indicate that NTHi infection stimulates a host innate immune response and further elevates cytokine gene expression, but that NTHi infection itself does not exacerbate hypoxia and HIF signalling.

By 7 days post-inoculation, NTHi infection is well established in the *Junbo* mouse ME and histology reveals an abscess-like structure with a core of necrotic neutrophils surrounded by viable and apoptotic neutrophils and foamy macrophages. The exudate neutrophil density is  $\sim 7 \times 10^6$  / $\mu$ l (Cheeseman et al., 2011) and 1-2 logs higher than viable NTHi ( $10^4$ - $10^5$  CFU/ $\mu$ l). We interpret the punctate and aggregate NTHi hybridization signals as intact single or clustered bacteria, or RNA released from lysed bacteria. Pus consists of neutrophils surrounded by neutrophil extracellular nets formed when the cell and nuclear membranes breakdown and release chromatin (Brinkmann and Zychlinsky, 2012). The extracellular histones formed in this process can have powerful antimicrobial effects and stimulate sterile inflammation via activation of the NLRP3 inflammasome (Allam et al., 2014). The impact of the host innate immune response on NTHi population dynamics will be a key determinant of changes in host-microbe interaction and disease and requires further investigation. Also, there are major implications concerning the extreme bottleneck occurring in the pathogenesis of OM, indicated by the monoclonal cultures (strain 375 or 162lux but not both) of ME exudate. Once initiated, ME infection rates remain high up to 14 days post-inoculation; it is not known whether NTHi titers were held in check by the immune response and/or other mechanisms such as host sequestration of nutrients, for example iron (Szelestey et al., 2013), contribute to limiting NTHi population growth. Unlike the infected ME of the chinchilla where NTHi is known to form a biofilm, our immunohistochemical and in situ hybridization analyses provided no clear evidence consistent with this mode of bacterial growth in the *Junbo* mouse ME bulla. It is likely that the inflamed hypoxic environment and

the high incidence of other microbial flora that can exist in the *Junbo* mouse ME present a substantially different growth challenge for NTHi than that provided when infecting the sterile chinchilla ME (Jurcisek and Bakaletz, 2007, Brockson et al., 2014). The maintenance of NTHi infection in the mouse for periods of at least 8 weeks provides an opportunity to carry out longitudinal infection studies whereby the host response and concomitant microbial within host adaptation and population dynamics can be studied and compared over time within and between individual mice.

Having established the basic dynamics of NTHi infection in the *Junbo* mouse we carried out two translational studies using quantitative end points. We have shown significant protection of the *Junbo* mouse following immunization with killed NTHi bacteria then IN challenge with the homologous NTHi strain. *Junbo* mice immunized with heterologous NTHi strains then infected with NTHi 162sr failed to show protection as indicated by infection rate, but some reduction in ME titer was observed. This likely reflects the substantial genetic and phenotypic heterogeneity that exists within natural populations of NTHi and the implicit challenge in developing a vaccine against NTHi OM and other diseases. These data offer proof in principle that the *Junbo* infection model could be used for relatively high throughput screening of candidate NTHi vaccine antigens. In clinical practice, antibiotic resistance is on the increase for NTHi and will potentially have a major impact on OM treatment regimens. The *Junbo* mouse model has demonstrated potential utility for investigating improved antibiotic treatments. A 3-day treatment of NTHi infected mice with systemic Azithromycin cleared ME infection, opening the possibility for the model to be used to either screen novel antibiotics for treatment, or design improved regimens and routes of delivery. An important feature of the *Junbo* OM model for future studies is the inflammatory thickening of the TM (Parkinson et al., 2006) as seen in human patients (Berger et al., 1996), making it a suitable model for testing trans-TM delivery of antibiotics.

In summary, mouse models offer the general advantages of relatively low costs, better availability of immunological reagents, and ease of control of host genetics and microbial status. In this study we tested 3 mouse lines *Junbo*, *Tgif* and *Jeff*, each with a characterised mutation mediating a differing susceptibility to NTHi infection. Several genes associated with increased susceptibility to spontaneous OM in the mouse have now been shown to be relevant to human disease through candidate gene studies in family-based cohorts (Rye et al., 2010). As new candidate human OM disease genes are discovered, their role in NTHi susceptibility could be investigated through the use of genetically modified mouse models. The high efficiency and reproducibility of IN inoculation in the *Junbo* mouse provides a robust platform to investigate aspects of host-microbial interaction, and the innate immune response to NTHi, and to test an adaptive immune response and antibiotic treatment against NTHi which have wide translational potential for clinical intervention. Lastly the *Junbo* model uses a non-invasive IN challenge route and a single terminal assessment, rather than re-sampling the same animal, and therefore represents welfare refinement.

## **MATERIALS AND METHODS**

### **Ethics statement**

Full details of these studies were reviewed and approved by MRC Harwell ethical review committee. The humane care and use of mice in this study was carried out under the authority of the appropriate UK Home Office Project License.

### **Mouse strains**

The majority of experiments used *Junbo* mice that were congenic on a C3H/HeH genetic background (Parkinson et al., 2006) and this mouse strain is available from the European Mouse Mutant Archive (EM:00091). For non-academic groups the *Junbo* model is available through MRC Technology.

<http://www.licensingopportunities.co.uk/research-tools/79/otitis-media/>

For comparative purposes *Junbo* mice congenic on a BALB/c background were used in other infection studies. *Tgif* mice were congenic on a C57BL/6J background (Tateossian et al., 2013) and *Jeff* mice (EM:00375) (Hardisty-Hughes et al., 2006) were on a mixed C3H/HeH and C57BL/6J genetic background.

### **Husbandry and microbiological surveillance of SPF *Junbo*, *Tgif* and *Jeff* mice**

SPF mice were housed in individually ventilated cages (Tecniplast) under a 12-hr light/12-hr dark cycle, temperature of  $21 \pm 2^\circ\text{C}$  and humidity of  $55 \pm 10\%$  on autoclaved Datesand grade 6 pine bedding. Mice were fed an irradiated expanded RM3 diet (Special Diets Services, Witham, UK), and given water ad libitum. Air changes were 70-75 per hr. Microbiological surveillance of sentinel mice from our SPF animal facility was performed by Harlan laboratories following the FELASA screening guidelines.

SPF mice that were challenged with bacteria were housed in a Biological Containment Unit IVC rack (Allentown) operated at negative pressure with an exhaust rate of  $35.7 \text{ m}^3$  per hr.

### **Generation and microbiological surveillance of germ free (GF) *Junbo* mice**

Germ Free C3H/HeJ stock was obtained from the CDTA-CNRS (Orleans, France). GF *Junbo* and C3H/HeH mice were re-derived by hysterectomy on day E19.5 of pregnancy to establish a breeding colony. GF mice were reared on irradiated Alpha-Dri substrate (SPP), plus shredded paper bedding and were housed in wire-topped cages within sterile flexible film isolators (Harlan-Isotec) fitted with DPTE alpha ports (La Calhene). GF mice were provided irradiated RM3 diet and autoclaved water ad libitum.

The isolators were maintained under positive pressure (5 to 10 mm water) operated at 12-15 air changes per hr. Feces, urine and bedding were tested every 4 weeks for the presence of fungi, anaerobic and aerobic bacteria using Sabourauds media (Becton

Dickinson), Thioglycolate media (Becton Dickinson) and nutrient broth (Becton Dickinson), respectively.

### **Histology, immunohistochemistry and in situ hybridization**

Middle ear histology in GF and SPF mice was assessed in Haematoxylin and Eosin stained sections of 3  $\mu\text{m}$  wax sections as previously described (Cheeseman et al., 2011).

To examine the histology of NTHi infected bullae by immunohistochemistry ( $n=6$ ) or by in situ hybridization and lesion profiling, 11-week-old *Jbo/+* mice ( $n=6$ ) were inoculated IN with  $10^6$  CFU NTHi 162 and heads collected 7 days post-inoculation were fixed 48 hours in neutral buffered formalin. Non-challenged *Jbo/+* mice ( $n=5$ ) collected at the same time served as negative controls. For immunohistochemistry EDTA decalcification was 5-7 days. To maximize RNA integrity for in situ work, a band saw was used to isolate the bullae from fixed heads and EDTA decalcification achieved in 48 hours.

For immunohistochemistry 4  $\mu\text{m}$  thick wax sections were cut onto electrostatically charged slides and dried overnight at 37°C before a final drying at 60°C for 25 minutes. Sections were de-waxed in xylene, hydrated through ethanol and washed three times in Tris Buffer. Endogenous peroxidase was blocked using Dako REAL peroxidase blocker (S2023) for 10 minutes following antibody incubations.

Rat monoclonal anti F4/80 (Serotec MCA497G) was used to detect macrophages. Antigen retrieval was performed using Dako proteinase K (S3020) for 20 minutes at room temperature. The antibody was diluted 1/400 and incubated for 30 minutes at room temperature. Secondary detection was carried out using the Vector Labs ImmPress HRP anti rat kit (MP-744-15) as per the manufacturer's instructions. Rabbit polyclonal anti cleaved Caspase 3 (Abcam ab2302) was used to detect apoptotic cells, and Rabbit polyclonal anti Histone 3 (Abcam ab61251) to detect histones. Antigen retrieval was carried out using Vector High pH antigen retrieval reagent at 60°C for 12 hrs. The rabbit polyclonal antibodies

were diluted 1/20 or 1/50 for Caspase 3 and Histone 3 respectively and incubated for 60 minutes at room temperature. Secondary detection was carried out using Dako (K4011) Envision+ System HRP anti Rabbit as per the manufacturer's instructions. Antibodies were diluted in Dako antibody diluent (S0809) and negative controls were carried out using the antibody diluent alone. Visualisation was achieved using Dako (K3468) liquid DAB+ substrate chromogen system. Counterstaining was carried out using Harris haematoxylin prior to dehydration through ethanol, clearing in xylene and mounting in Clearview mountant (Thermo Fisher Scientific).

For lesion profiling, bright field images of Haematoxylin and Eosin stained sections were acquired using a Hamamatsu NanoZoomer slide scanner and the morphometric measurements were made using NanoZoomer software. The average thickness of the mucosa lining the medial surface of the bulla (avoiding the cochlea and the region close to the Eustachian tube) was calculated by dividing the area of mucosa overlying delineated ~1000  $\mu\text{m}$  length of supporting bulla bone. The proportion of bulla space occupied by exudate was calculated by dividing the exudate area by the area bounded by bulla mucosa surface and the tympanic membrane. The treatment groups were blinded for the slide analysis.

In situ hybridization was performed on 4  $\mu\text{m}$  wax sections of representative NTHi challenged ( $n=2$ ) and non-challenged ( $n=2$ ) *Jbo/+* mice heads using probe B-HInfluenzae-NTHi375-16SrRNA as per the manufacturer's instructions (Advanced Cell Diagnostic) using the HRP visualisation kit. A positive control for RNA integrity (PpiB) and a negative hybridization control (DapB) (Advanced Cell Diagnostic) were used.

### **Intranasal administration of FITC microspheres**

Nine week old *Jbo/+* ( $n=6$ ) and wild-type littermate ( $n=9$ ) mice were anaesthetized with isoflurane and  $\sim 10^8$  FITC-microsphere beads (1.0  $\mu\text{m}$  blue-green fluorescent (430/465) polystyrene microspheres, Life Technologies) administered IN by applying 5  $\mu\text{l}$  of

suspension to each nostril. The mice were euthanized at ~5 minutes using a rising concentration of CO<sub>2</sub> and the heads fixed in neutral buffered formalin. EDTA decalcified heads were prepared for cryostat sectioning of the ET. Ten µm coronal serial sections of the ET were mounted on consecutive slides. A representative slide with range of ET levels was counterstained with DAPI and mounted in Prolong antifade reagent (Molecular Probes). The sections were scanned and the number of FITC microspheres were counted in representative levels of each ET and expressed per mm of ET profile. The mouse genotypes were blinded for the slide analysis.

### **Bacterial strains for inoculum preparation and immunization**

NTHi strains used in the study are well characterised, phylogenetically distinct strains (162, 176, 285, 375, 486, 1124, 1158) from human OM (Cody et al., 2003), and 2019. Growth of indigenous commensal bacterial flora, particularly of *Proteus* spp., rendered a proportion of bacterial count plates unreadable. For this reason, NTHi strains expressing resistance to streptomycin or kanamycin (eg NTHi 162sr or 162kr) were generated. Spontaneous streptomycin resistant colonies were selected after plating bacteria at high density ( $2 \times 10^{10}$  CFU/plate) on streptomycin (300 µg/ml) containing media. Strain 162kr was made through insertion of a kanamycin resistance cassette onto a position in the NTHi genome (HI0227) that had no characterized phenotype. These strains enabled antibiotic selection of NTHi during culture and counter-selection against any indigenous bacteria; this increased the number of ME providing quantitative data during experiments.

Strain NTHi 162lux was constructed by transforming strain 162 with the *luxCDABE* genes using chromosomal DNA isolated from *H. influenzae* strain Xen21 (Caliper Life Sciences).

Bacteria from -80°C stocks were grown overnight at 37°C in 5% CO<sub>2</sub> atmosphere on Brain Heart Infusion-Levinthals (BHI-Lev) agar then used to inoculate BHI-Lev broth and

grown to log-phase prior to preparing the animal inoculum. Inoculum size was calculated from optical density measurement using the conversion factor that an OD  $A_{490}$  of 0.4 =  $1 \times 10^9$  CFU/ml. Bacteria were pelleted by centrifugation at 13000xg for 3 minutes then re-suspended to  $10^{10}$  CFU/ml in PBS/2% gelatin. The titer of each inoculum was assessed pre- and post-inoculation by dilution and plating.

For subcutaneous immunization of mice, bacteria from liquid culture were pelleted, resuspended in PBS then killed by treatment with 1% paraformaldehyde (PFA) (1hr at 37°C, then overnight at 4°C); loss of viability was confirmed by plating. Killed NTHi were stored in 1% PFA for up to 5 weeks at 4°C and their integrity assessed by phase contrast microscopy. Before use, the bacteria were pelleted by centrifugation at 13000xg for 3 minutes and re-suspended to give  $10^{10}$  CFU/ml in PBS then mixed with Adjuvax (Sigma) adjuvant according to the manufacturer's instructions.

### **Intranasal challenge**

SPF mice aged either  $8 \pm 1$  week or  $12 \pm 1$  week were anesthetized with isoflurane and 5  $\mu$ l of the  $10^8$  CFU inoculum applied to each nostril. For each time point in an experiment, mice in cohorts of 11-15 animals were inoculated with doses ranging from  $10^3$  -  $10^8$  CFU.

### **Terminal sampling of blood, bulla fluids and nasopharynx**

Bulla fluids were sampled terminally via the TM as previously described (Cheeseman et al., 2011) and the volume estimated using 0-2  $\mu$ l filtered pipette tip (average volume 0.5  $\mu$ l, range 0.1-1.25  $\mu$ l) then transferred into 500  $\mu$ l of PBS. In wild-type mice and in a proportion of *Jbo*<sup>+</sup> ME, the TM was clear and there was no detectable bulla fluid. These bullae were washed twice with 2  $\mu$ l of sterile PBS and the washings added back to 500  $\mu$ l of PBS.

In some experiments the NP was sampled after collecting bulla fluids by washing with 200  $\mu$ l PBS introduced into the NP opening on the palate and collecting the wash fluid from the nares. To ensure this order of collection did not displace ME NTHi and bias NP



numbers recovered, the NP was sampled first in one cohort of  $n=15$  mice; the infection rate was found to be not significantly different (67% versus 80%  $P=0.6816$ , Fisher exact test  $n=15$  mice per group) and the titers comparable when the NP is sampled either before or after the ME ( $10^{1.1}$  and  $10^{1.6}$  respectively).

### **NTHi culture of ME bulla fluids and NP wash.**

Bulla fluids and NP washes in PBS were mixed by three 10 sec bursts on a vortex mixer then 10-fold dilutions ( $10^{-1}$ ,  $10^{-2}$ ) were made in PBS. 50  $\mu$ l of each ME dilution or NP wash was spread on a BHI-Lev agar plate. The detection limit was 10 CFU/ $\mu$ l for the primary bulla fluid preparation and 100 CFU/ $\mu$ l for the  $10^{-1}$  dilution. The primary bulla fluid suspension was centrifuged at 13000xg for 3 minutes and the pellet frozen on dry ice then stored at  $-80^{\circ}\text{C}$  for RNA isolation (see below).

In experiments using antibiotic resistant strains, bulla samples were plated on media supplemented with 300  $\mu\text{g/ml}$  streptomycin or 30  $\mu\text{g/ml}$  kanamycin. The ME commensal bacteria were assessed using a non-selective plate in parallel. Plates were cultured overnight at  $37^{\circ}\text{C}$  to calculate NTHi titers. Representative NTHi colonies were examined by phase contrast microscopy to confirm its small coccobacillus morphology.

In the co-infection experiment with NTHi 162lux and 375 ( $5 \times 10^5$  CFU each strain IN), a monoculture is defined as  $\geq 10$  colonies all of the same strain (either 162lux or 375) on the BHI primary culture plate.

### **Infection rates and bulla fluid titer**

To compare ME infection rates we used an index of infected bulla fluids:

$$\frac{\text{NTHi positive bulla cultures}}{\text{NTHi positive cultures} + \text{NTHi negative cultures}}$$

Two categories were excluded from this index: PBS bulla washes (because they yielded a very low percentage with NTHi growth) and, in experiments using non-antibiotic resistant NTHi strains, bulla fluids that gave *Proteus* overgrowth preventing NTHi detection. The ME NTHi titer (CFU/ $\mu$ l) was calculated from plate counts, sample dilution and bulla fluid volume.

### **Bioluminescent imaging**

Mice were inoculated with NTHi 162lux and bioluminescent signals from the head (oral cavity aspect of the palate after dissecting away the mandible) or, for dual infection studies, the proportion of NTHi colonies on the BHI ME culture plates were imaged using an IVIS Lumina II system (Perkin Elmer).

### **Real time quantitative PCR (RT-qPCR) of bulla fluids**

8 week old SPF *Jbo/+* mice were inoculated with  $10^6$  CFU NTHi 375 and cohorts were sampled terminally at days 1, 3, 7, 10 and 14 post-inoculation. Cell pellets ( $n=4-6$ ) were pooled from bulla fluids that yielded NTHi monocultures on the  $10^{-1}$  dilution plate (equivalent to  $<100$  CFU/ $\mu$ l commensal bacterial) and for each time point there were  $n=3-6$  biological replicate pools. Bulla fluids from 8-10 week old GF *Jbo/+* mice were collected into 20  $\mu$ l of RNase free water for RNA isolation and used as a baseline expression control. Each GF pool comprised  $n=4-6$  bulla fluids and there were  $n=10$  biological replicates. RNA extraction, cDNA synthesis and RT-qPCR TaqMan were performed as previously described (Cheeseman et al., 2011) for *Ccl3*, *Ccl4*, *Ccl5*, *IL-1b*, *IL-6*, *IL-12a*, *IL-17a*, *Tnfa* and *Vegfa*. RT-qPCR was performed in triplicate technical assays. Data was normalized using *Hrpt1* and beta Actin as the endogenous control and fold changes of expression (ddCts) of NTHi infected bulla fluid white blood cells over non-infected white blood cells were calculated

using AB 7500 software v2.0.1 and expressed as mean relative quantification (RQ)  $\pm$  min/max error bars representing 95% CI.

### **Immunization with NTHi bacteria**

Each *Jbo*/<sup>+</sup> mouse received 3 subcutaneous immunizations in intra-scapular skin with 10<sup>8</sup> CFU killed bacteria and adjuvant in 50  $\mu$ l. Immunizations were at the age of 5, 8 and 10 week. Mice were immunized with either NTHi 162sr, 176 or 375 then inoculated IN at 12 weeks with 10<sup>6</sup> CFU NTHi 162sr. ME infection was assessed at 7 days post-inoculation.

### **Azithromycin treatment of NTHi infection**

8-week-old *Jbo*/<sup>+</sup> mice were treated using a 3-day course of 100 mg/kg Azithromycin delivered once a day by oral gavage. Treatment started at day 4 post IN-inoculation with 10<sup>6</sup> CFU NTHi 162 and bulla fluids sampled on day 7. A sham-treated control group was gavaged with vehicle alone (2% methoxycellulose solution). The MIC for NTHi 162 was determined to be 1  $\mu$ g/ml.

### **Statistical analysis**

Log<sub>10</sub> normalized NTHi titers were analyzed using t-tests (mouse strain susceptibility data, immunization data and antimicrobial data) or by one-way ANOVAs and Tukeys multiple comparison tests for post-hoc testing (inoculation dose data and 24 hr time course data). ME mucosa thickness, bulla fluid area proportions and microsphere counts per mm of ET were analyzed with a Mann-Whitney test. Fisher exact and Chi-squared tests were used to analyze frequency data (TM phenotypes, occurrence of bulla fluids, ME and NP infection rates). Data are presented as mean  $\pm$  SE, mean  $\pm$  95% CI, or median  $\pm$  95% CI. 2-tailed test values  $P < 0.05$  were considered significant.

## **ACKNOWLEDGEMENTS**

We thank the staff in Mary Lyon Centre, Andy Hinton, Lucie Vizor, Mark Harrison and Alison Gallop for the husbandry and humane care of these mice; pathology and histology teams; the genotyping core; and imaging. Neil Macintyre and Sharon Moss of Easter Bush Pathology, Royal (Dick) School of Veterinary Studies, performed the immunohistochemistry and prepared the cryosections.

## **COMPETING INTERESTS**

The authors declare no competing or financial interests.

## **AUTHOR CONTRIBUTIONS**

D.H., R.M., S.D.M.B., M.F. and M.T.C. conceived and designed the experiments. D.H., T.P., C.R., D.W., A.A., M.C., S.W., M.F., M.T.C. performed the experiments. D.H., C.R., D.W. and M.T.C. analyzed the data. D.H., R.M. and M.T.C. wrote the paper.

## **FUNDING**

This work was supported by the Medical Research Council Technology Development Gap Fund Award (A853-0114 to M.T.C.), the MRC, the University of Oxford Department of Paediatrics Emeritus Fund (H5420 to R.M.) and a BBSRC Institute Strategic Programme grant to The Roslin Institute.


## REFERENCES

1. **Allam, R., Kumar, S.V., Darisipudi, M.N., Anders, H.J.** (2014) Extracellular histones in tissue injury and inflammation. *J. Mol. Med. (Berl)*. 92, 465-472.
2. **Bakaletz, L.O.** 2009. Chinchilla as a robust, reproducible and polymicrobial model of otitis media and its prevention. *Expert Review of Vaccines*. 8, 1063-1082.
3. **Benninger, M.S.** (2008). Acute bacterial rhinosinusitis and otitis media: changes in pathogenicity following widespread use of pneumococcal conjugate vaccine. *Otolaryngol. Head Neck Surg*. 138, 274-278.
4. **Berger, G., Sachs, Z., Sadé, J.** (1996). Histopathologic changes of the tympanic membrane in acute and secretory otitis media. *Ann. Otol. Rhinol. Laryngol*. 105, 458-462.
5. **Bouchet, V., Hood, D.W., Li, J., Brisson, J.R., Randle, G.A., Martin, A., Li, Z., Goldstein, R., Schweda, E.K., Pelton, S.I., et al.** (2003). Host-derived sialic acid is incorporated into Haemophilus influenzae lipopolysaccharide and is a major virulence factor in experimental otitis media. *Proc. Natl. Acad. Sci. U. S. A.* 100, 8898-8903.
6. **Brinkmann, V., Zychlinsky, A.** (2012). Neutrophil extracellular traps: is immunity the second function of chromatin? *J. Cell Biol.* 198, 773-783.
7. **Brockson, M.E., Novotny, L.A., Mokrzan, E.M., Malhotra, S., Jurcisek, J.A., Akbar, R., Devaraj, A., Goodman, S.D., Bakaletz, L.O.** (2014) Evaluation of the kinetics and mechanism of action of anti-integration host factor-mediated disruption of bacterial biofilms. *Mol. Microbiol.* 93, 9, e1003709
8. **Cheeseman, M.T., Tyrer, H.E., Williams, D., Hough, T.A., Pathak, P., Romero, M.R., Hilton, H., Bali, S., Parker, A., Vizor, L., et al.** (2011). HIF-VEGF pathways are critical for chronic otitis media in Junbo and Jeff mouse mutants. *PLoS Genet.* 10, e1002336.
9. **Cody, A.J., Field, D., Feil, E.J., Stringer, S., Deadman, M.E., Tsolaki, A.G., Gratz, B., Bouchet, V., Goldstein, R., Hood, D.W., et al.** (2003). High rates of recombination in otitis media isolates of non-typeable Haemophilus influenzae. *Infect. Genet. Evol.* 3, 57-66.
10. **Giebink, G.S., Payne, E.E., Mills, E.L., Juhn, S.K., Quie, P.G.** (1976) Experimental otitis media due to Streptococcus pneumoniae: immunopathogenic response in the chinchilla. *J. Infect. Dis.* 134, 595-604.
11. **Giebink, G.S., Berzins, I.K., Schiffman, G., Quie, P.G.** (1979) Experimental otitis media in chinchillas following nasal colonization with type 7F Streptococcus pneumoniae: prevention after vaccination with pneumococcal capsular polysaccharide. *J. Infect. Dis.* 140, 716-723.
12. **Giebink, G.S.** (1981) The pathogenesis of pneumococcal otitis media in chinchillas and the efficacy of vaccination in prophylaxis. *Rev Infect. Dis.* 3, 342-353.
13. **Hardisty-Hughes, R.E., Tateossian, H., Morse, S.A., Romero M.R., Middleton, A., Tymowska-Lalanne, Z., Hunter, A.J., Cheeseman, M., Brown, S.D.** (2006). A mutation in the F-box gene, Fbxo11, causes otitis media in the Jeff mouse. *Hum. Mol. Genet.* 15, 3273-3279.

14. **Haste, L., Hulland, K., Bolton, S., Yesilkaya, H., McKechnie, K., Andrew, P.W.** (2014). Development and characterization of a long-term murine model of *Streptococcus pneumoniae* infection of the lower airways. *Infect. Immun.* 82, 3289-3298.
15. **Hernandez, M., Leichtle, A., Pak, K., Webster, N.J., Wasserman, S.I., Ryan, A.F** (2015). The transcriptome of a complete episode of acute otitis media. *BMC Genomics.* 16, 259
16. **Juhn, S.K., Jung, M.K., Hoffman, M.D., Drew, B.R., Preciado D.A., Sausen, N.J., Jung, T.T., Kim, B.H., Park, S.Y., Lin, J., et al.** (2008). The role of inflammatory mediators in the pathogenesis of otitis media and sequelae. *Clin. Exp. Otorhinolaryngol.* 1, 117-138.
17. **Jurcisek, J.A. and Bakaletz, L.O.** (2007). Biofilms formed by non-typeable *Haemophilus influenzae* in vivo contain both dsDNA as well as type IV pilin protein. *J. Bacteriol.* 189, 3868-3875.
18. **Kaur, R., Casey, J., Pichichero, M.** (2015). Cytokine, chemokine, and Toll-like receptor expression in middle ear fluids of children with acute otitis media. *Laryngoscope.* 125, E39-44.
19. **Leichtle, A., Hernandez, M., Pak, K., Yamasaki, K., Cheng, C.F., Webster, N.J., Ryan, A.F., Wasserman, S.I.** (2009). TLR4-mediated induction of TLR2 signaling is critical in the pathogenesis and resolution of otitis media. *Innate Immun.* 15, 205-215.
20. **Leichtle, A., Lai, Y., Wollenberg, B., Wasserman, S.I., Ryan, A.F.** (2011). Innate signaling in otitis media: pathogenesis and recovery. *Curr. Allergy Asthma Rep.* 11, 78-84.
21. **Leichtle, A., Hernandez, M., Lee, J., Pak, K., Webster, N.J., Wollenberg, B., Wasserman, S.I., Ryan, A.F.** (2012). The role of DNA sensing and innate immune receptor TLR9 in otitis media. *Innate Immun.* 18, 3-13.
22. **Li, J.D., Hermansson, A., Ryan, A.F., Bakaletz, L.O., Brown, S.D., Cheeseman, M.T., Juhn, S.K., Jung, T.T., Lim, D.J., Lim, J.H., et al.** (2013). Panel 4: Recent advances in otitis media in molecular biology, biochemistry, genetics, and animal models. *Otolaryngol. Head Neck Surg.* 148(4 Suppl), E52-63.
23. **Maronpot, R.R., Boorman, G.A., Gaul, B.W.** (1999.) *Pathology of the Mouse: Reference and Atlas*, Cache River Press.
24. **McCullers, J.A., Karlström, A., Iverson, A.R., Loeffler, J.M., Fischetti, V.A.** (2007). Novel strategy to prevent otitis media caused by colonizing *Streptococcus pneumoniae*. *PLoS Pathog.* 3, e28.
25. **Monasta, L., Ronfani, L., Marchetti, F., Montico, M., Vecchi Brumatti, L., Bavcar, A., Grasso, D., Barbiero, C., Tamburlini, G.** (2010). Burden of disease caused by otitis media: systematic review and global estimates. *PLoS One.* 7, e36226.
26. **Parkinson, N., Hardisty-Hughes, R.E., Tateossian, H., Tsai, H.T., Brooker, D., Morse, S., Lalane, Z., MacKenzie, F., Fray, M., Glenister, P., et al.** (2006). Mutation at the *Evi1* locus in Junbo mice causes susceptibility to otitis media. *PLoS Genet.* 2, e149.
27. **Roos, A.B., Sethi, S., Nikota, J., Wrona, C.T., Dorrington, M.G., Sandén, C., Bauer, C.M., Shen, P., Bowdish, D., Stevenson, C.S., et al.** (2015). IL-17A and the


- promotion of neutrophilia in acute exacerbation of chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* 192,428-437.
28. **Ryan, A.F., Ebmeyer, J., Furukawa, M., Pak, K., Melhus, A., Wasserman, S.I., Chung, W.H.** (2006). Mouse models of induced otitis media. *Brain Res.* 1091, 3-8.
  29. **Rye, M.S., Bhutta, M.F., Cheeseman, M.T., Burgner, D., Blackwell, J.M., Brown, S.D., Jamieson, S.E.** (2010). Unraveling the genetics of otitis media - from mouse to human and back again. *Mamm. Genome.* 22, 66–82.
  30. **Sabirov, A., Metzger, D.W.** (2006). Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media. *Vaccine.* 24, 5584-5592.
  31. **Sabirov, A., Metzger, D.W.** (2008). Mouse models for the study of mucosal vaccination against otitis media. *Vaccine.* 26,1501-1524.
  32. **Short, K.R., Reading, P.C., Brown, L.E., Pedersen, J., Gilbertson, B., Job, E.R., Edenborough, K.M., Habets, M.N., Zomer, A., Hermans, P.W., et al.** (2013). Influenza-induced inflammation drives pneumococcal otitis media. *Infect. Immun.* 81, 645-652
  33. **Stol, K., van Selm, S., van den Berg, S., Bootsma, H.J., Blokk, W.A., Graamans, K., Tonnaer, E.L., Hermans, P.W.** (2009). Development of a non-invasive murine infection model for acute otitis media. *Microbiology.* 155, 4135-4144.
  34. **Szelestey, B.R., Heimlich, D.R., Raffel, F.K., Justice, S.S., Mason, K.M.** (2013). Haemophilus responses to nutritional immunity: epigenetic and morphological contribution to biofilm architecture, invasion, persistence and disease severity. *PLoS Pathog.* 9, e1003709
  35. **Tateossian, H., Morse, S., Parker, A., Mburu, P., Warr, N., Acevedo-Arozena, A., Cheeseman, M., Wells, S., Brown, S.D.** (2013). Otitis media in the Tgfr1 knockout mouse implicates TGF $\beta$  signalling in chronic middle ear inflammatory disease. *Hum. Mol. Genet.* 22, 2553-2565.
  36. **Xu, X., Woo, C.H., Steere, R.R., Lee, B.C., Huang, Y., Wu, J., Pang, J., Lim, J.H., Xu, H., Zhang, W., et al.** (2012). EVI1 acts as an inducible negative-feedback regulator of NF- $\kappa$ B by inhibiting p65 acetylation. *J Immunol.* 188, 6371-6380.

## Figures




**Fig. 1. IN-inoculation with different NTHi strains produces variation in ME infection rate and bacterial titer, but for NTHi 162 these parameters do not vary over a 10<sup>4</sup> to 10<sup>8</sup> CFU inoculum dose.** *Jbo*/+ mice were sampled 7 days post IN-inoculation with different NTHi strains (A) ME infection rates and (C) titers vary with NTHi strain. For NTHi 162 (B) ME infection rate and (D) titers were not significantly different when inoculum doses were used over the range of 10<sup>4</sup> -10<sup>8</sup> CFU; *n*=11-12 mice per cohort, data are represented as mean ± 95% CI. (B) Fisher exact test, (D) 1-way ANOVA; NS not significant.






**Fig. 2. Time course of NTHi ME infection.** (A) A bioluminescent signal from  $10^8$  CFU NTHi 162lux is evident level with opening of the NP (arrow) minutes after IN inoculation of three *Jbo/+* mice. A 24 hr time course for (B) ME infection rate and (D) log<sub>10</sub> titers in 12 week *Jbo/+* mice inoculated with  $10^6$  CFU NTHi 162sr (detection limit of 10 CFU/ $\mu$ l); extended time course from 1-56 days post-inoculation (detection limit of 100 CFU/ $\mu$ l) (C) ME infection rate and (E) log<sub>10</sub> titers;  $n=13-15$  mice per time point, data are represented as mean  $\pm$  95% CI. (D) 1-way ANOVA  $P<0.001$ ; using Tukeys multiple comparison tests, the NTHi titers at 1 hr, 3 hr and 6 hr are not significantly different from one another, however each is significantly different from the NTHi titer at 24 hr (\*\* $P<0.01$ ).




**Fig. 3. Histopathology of the *Jbo*/<sup>+</sup> mouse ME 7 days post inoculation with NTHi.**  
 Composite histological features from three 12 week *Jbo*/<sup>+</sup> mice 7 days post IN-inoculation

with  $10^6$  CFU NTHi 162. (A) and (B) a higher magnification inset of a Haematoxylin and Eosin stained section of ME bulla, tympanic membrane (tm) arrow. Bulla fluid has a caseous core of necrotic neutrophil leukocytes (c) surrounded by viable neutrophil leukocytes (nl) and foamy macrophages (fm); inflamed ME mucosa (m) and bulla bone (b). (C) F 4/80 antibody positive foamy macrophages in bulla fluid (fm) and macrophages in the inflamed mucosa (arrows). (D) and (E) a higher magnification inset of cleaved caspase 3 positive apoptotic cells (arrows). (F) Two of six bulla fluids had large extracellular accumulations of Haematoxylin positive chromatin (arrows). (G) The larger chromatin foci were histone 3 antibody negative (white arrows) but finely granular extracellular histone 3 positive material (black arrow) was scattered in the caseous core. Note normal histone staining of neutrophil and epithelial nuclei. (H) Neutrophils in Eustachian tube (et) lumen adjacent to the bulla opening and (I) at the nasopharynx junction (np) (black arrows), neutrophil leukocyte infiltration in ET submucosa (white arrows). (J, K) *Jbo/+* mouse inoculated with NTHi 162sr and probed with B-HInfluenzae-NTHi375-16SrRNA oligonucleotide (Advanced Cell Diagnostic) and visualized using HRP and DAB. Bulla fluid exudates have chromogen deposits (arrows) that appeared as scattered punctate signals ( $\sim 1 \mu\text{m}$ ) or irregular aggregates (10-20  $\mu\text{m}$  greatest dimension), the mucosa margin is marked (m). NTHi hybridisation signals were absent in non-inoculated *Jbo/+* control mice (L, M). A positive control probe (Ppib) for mouse RNA integrity showed punctate signals in mucosal epithelium and bulla fluid cells but no signal was obtained with a negative control probe (bacterial DapB gene) data not shown.


Scale bars A = 500  $\mu\text{m}$ , B,H = 200  $\mu\text{m}$ , C,D,F = 100  $\mu\text{m}$ , E,G,I = 50  $\mu\text{m}$ . Asterix (\*) marks an artefactual cleft caused by histology processing in panels A,C,F. J and L magnification x200 scale bar = 200  $\mu\text{m}$ , K and M x1000 oil immersion scale bar = 20  $\mu\text{m}$ .




**Fig. 4. *Jbo*/+ mice develop otitis media in germ free (GF) conditions.** (A) Time course of the proportion of *Jbo*/+ GF mice with unilateral or bilateral otitis media (the number of mice is indicated alongside each time point). Histological analysis of *Jbo*/+ mouse ME (B-F). (B) Haematoxylin and Eosin stained sections of non-inflamed ME of a 4 week GF *Jbo*/+ mouse with an air filled bulla space, thin mucosa (m) indicated between arrows, supported by underlying bulla bone (b); (C) inflamed ME of a 4 week SPF *Jbo*/+ mouse with exudate (e) in the bulla space, and thickened mucosa (m); (D-E) inflamed ME of GF *Jbo*/+ with bulla exudate (e) and thickened mucosa (m) at (D) 5 weeks of age ; and (E) 8 weeks of age; (F) ME exudate in a 12 week GF *Jbo*/+ mouse contains plant-based foreign body (fb) in bulla exudate (PAS stained section). Scale bars B-F= 50  $\mu$ m.




**Fig. 5. NTHi monocultures predominate 7 days after co-inoculation with two strains.** *Jbo/+* mice were co-inoculated with  $5 \times 10^5$  CFU each of NTHi 162lux and NTHi 375. (A) dual infections predominate on day 1 post infection, but single infections predominate on day 7; (B) the ME infection rate remains high from day 1-7; (C) ME titers are comparable for 162lux and 375 in co-infections. Data are represented as mean  $\pm$  95% CI and overlapping error bars are omitted; (D) the proportion of single infections with NTHi 162lux predominate at day 7. The number of monocultures is indicated alongside each time point.



**Fig. 6. Host innate immune response in NTHi infected bulla fluids.** ME infection rate (A) and titer (B) in 8 week *Jbo*<sup>+/+</sup> mice inoculated with 10<sup>6</sup> CFU NTHi 375 (*n*=12 per cohort) mean ± 95% CI. (C-E) modulation of gene expression in NTHi infected ME samples relative to GF ME samples detected by RT-qPCR. Each time point represents biological replicate pools of *n*=3-6 NTHi infected ears and *n*=10 biological replicate pools of GF bulla samples as baseline controls; data are represented as mean relative quantification (RQ) ± 95% CI.



**Fig.7. Homologous and heterologous protection for mice immunized with killed NTHi bacteria.** (A) *Jbo*<sup>+</sup> mice immunized 3 times subcutaneously with 10<sup>8</sup> killed NTHi 162 (but not 176 or 375) had a significantly lower ME infection rate when inoculated with 10<sup>6</sup> CFU NTHi 162sr compared to PBS immunized controls (B) *Jbo*<sup>+</sup> mice immunized with either killed NTHi 162, 176 or 375 had significantly lower ME titers than PBS controls. *n*=14-15 mice per cohort for NTHi 176 and 375 immunized mice and *n*=30 for NTHi 162 and PBS; data are represented as mean ± 95% CI. (A) Fisher exact tests comparing infection rates for each NTHi strain with the PBS control, (B) t-tests comparing titers for each NTHi strain with the PBS control; NS not significant, \*\**P*<0.01, \*\*\**P*<0.001.



**Fig. 8. Azithromycin treatment eliminates NTHi infection.** Time course of (A) ME infection rate and (C) titer for 8 week *Jbo*/*+* mice inoculated with  $10^6$  CFU NTHi 162 ( $n=11-12$  per time point). (B,D) *Jbo*/*+* mice were treated with 100 mg/kg Azithromycin (AZM) by oral gavage once a day for 3 days starting on day 4 post-inoculation with  $10^6$  CFU NTHi 162, and sampled at day 7. (B) ME infection rate was significantly reduced in the AZM treatment group. (D) NTHi titer in the vehicle treated group was  $10^{5.3}$  CFU/ $\mu$ l ( $10^{5.1}-10^{5.4}$ ) whereas NTHi were not detected in the AZM treated group (detection limit  $10^2$  CFU/ $\mu$ l),  $n=15$  *Jbo*/*+* per group. Data are represented as mean  $\pm$  95% CI. (A) Fisher exact test, (B) 1-sample t-test using a hypothetical sample mean of  $10^2$  CFU/ $\mu$ l; \*\*\* $P<0.001$



## TRANSLATIONAL IMPACT

### Clinical Issue

Acute otitis media, inflammation of the middle ear, is the most common bacterial infection in children and reason for antimicrobial prescription to this age group. There is currently no effective vaccine for the principal pathogen, non-typeable *Haemophilus influenzae* (NTHi) and oral antibiotics have marginal clinical benefit.

The chinchilla is the standard animal model for AOM vaccine research and uses direct injection of bacteria into the middle ear. The natural route of middle ear infection is by nasal bacteria ascending via the Eustachian tube. Middle ear infection via intranasal inoculation requires barotrauma to translocate bacteria or co-infection with viruses. The mouse is an alternative model for NTHi infection studies. The role of innate immunity genes on susceptibility to otitis media has been intensively studied in genetically altered mice using the wide range of reagents available for protein and gene expression analyses in this species. Following intranasal challenge NTHi infection in wild-type mice resolves spontaneously within 7 days.

### Results

We have modeled NTHi infection in specific pathogen free *Junbo* mice. The *Junbo* mouse bears a mutation in the *Evi1* (Mecom) transcription factor, an inducible negative regulator of NFkB, the transcription factor that is the master regulator of inflammatory networks. The *Junbo* mouse spontaneously develops inflammatory disease that is restricted to the middle ear; this inflammation predisposes mice to middle ear infection after a single intranasal inoculation of NTHi. Middle ear infection rate and NTHi titers peak between 4-14 days post inoculation followed by clearance. 20% of middle ears remain infected after 56 days. The high infection rate and bacterial titer achieved in the bulla fluids makes the *Junbo* mouse a reproducible model to study interventions and we show protection by immunization with killed homologous NTHi strains and infection clearance using oral Azithromycin.

### Implications and future directions

The *Junbo* infection model has utility for translational studies. Small cohorts of mice are sufficient to screen individual candidate antigens and/or immunization routes for vaccination. Inflammatory disease of the middle ear in humans and *Junbo* mice causes thickening of the tympanic membrane. The model is potentially useful to develop ototopical delivery systems to improve therapeutic response, reduce the use of oral antibiotics and thereby the risk of

emerging antibiotic resistance. The *Junbo* model is available to researchers through the European Mouse Mutant Archive and MRC Technology.